Shamburg News · 8-K filed Nov 4, 2026, 4:51 PM EST

Summit Therapeutics Reports Q3 2026 Results; Stockholders Approve Authorized Share Increase

SMMT · Summit Therapeutics Inc.

  • Earnings
  • Shareholder vote
  • Other event
  • Materiality: high

Summit Therapeutics reported a GAAP net loss of $208.4 million, or $(0.26) per basic and diluted share, for the third quarter ended September 30, 2026, compared with $(0.31) a year earlier, and cash and investments of $629.8 million at quarter end. Non-GAAP net loss was $160.7 million, or $(0.20) per share. On November 4, 2026, stockholders at a Special Meeting approved an amendment increasing authorized common stock from 1,000,000,000 to 2,000,000,000 shares, which was filed and became effective the same day. The company also described its ivonescimab clinical program and the $2.0 billion AstraZeneca equity investment completed October 5, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 5.03, 5.07, 9.01, accession 0001599298-26-000088.

Written from the filing by Shamburg Markets. Figures are as reported by the company.